PTCy GVHD prophylaxis after allogeneic stem cell transplant yields comparable relapse incidence, lower GVHD
By Elana Gotkine HealthDay Reporter
MONDAY, June 24, 2024 (HealthDay News) — For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields comparable relapse incidence (RI) and significantly lower incidence of GVHD than conventional prophylaxis, according to a study published online June 10 in the American Journal of Hematology.
Arnon Nagler, M.D., from the Sheba Medical Center in Tel Hashomer, Israel, and colleagues compared RI post-unrelated allogeneic stem cell transplantation with PTCy versus conventional GVHD prophylaxis among 7,049 AML patients in remission (707 with PTCy; 6,342 with No PTCy).
The researchers found that RI did not differ significantly in the PTCy versus the no PTCy group. The PTCy group had significantly lower acute GVHD grades II to IV and III to IV versus the No PTCy group (hazard ratios, 0.74 and 0.56, respectively), and total and extensive chronic GVHD (hazard ratios, 0.5 and 0.31, respectively). Compared with the No PTCy group, the PTCy group had significantly lower nonrelapse mortality (hazard ratio, 0.67). Significantly higher GVHD-free, relapse-free survival was seen in the PTCy versus the No PTCy group (hazard ratio, 0.69). The groups did not differ in terms of leukemia-free survival or overall survival.
“Clinically, these results are of importance, and although not direct proof, they may indicate that PTCy does not jeopardize the graft-versus-leukemia effect in the unrelated donor setting,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
